The General Assembly of the Egyptian International Pharmaceutical Industries Company (EIPICO) has officially approved the financial results for the 2025 fiscal year, praising the company’s exceptional performance across all sectors. 
 
 During the meeting, shareholders renewed their full confidence in the Board of Directors, led by Chairman and Managing Director, Dr. Ahmed Kelani.
 
 Dr.Ahmed Kelani announced that EIPICO has successfully achieved its 2025 strategic targets, reaching a production value of EGP 10.8 billion and sales of EGP 9.8 billion. 
 
 On the international front, the company continues to lead the sector with USD 60.3 million in exports, representing 26% of all Egyptian pharmaceutical exports.
 
 "Our financial position remains robust," Dr. Ahmed Kelani stated, noting that the development of the Arab Company for Active Pharmaceutical Ingredients ( ARAB API ) is proceeding strictly according to schedule.
 
 Addressing the current regional climate, Dr. Ahmed Kelani emphasized EIPICO ’s national duty as the largest subsidiary of ACDIMA Egypt. To ensure market stability, the company has secured a strategic stockpile of production materials sufficient for at least the next 8 months. 
 
 Dr. Ahmed Kelani concluded by thanking the shareholders and the company’s employees—whom he described as EIPICO ’s "true capital"—for their unwavering dedication.